Trial Profile
A multi-centre randomized, double-blind study comparing adalimumab (D2E7) plus methotrexate with placebo plus methotrexate on work disability in subjects with early rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.
- 20 Nov 2008 New trial record.
- 20 Nov 2008 Results have been published in Arthritis & Rheumatism.